Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 20/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22975871 | 0.90 | NT5E (0.53) | NT5E | |
| SCHEMBL31757506 | 0.90 | NT5E (0.56) | NT5E | |
| SCHEMBL20180063 | 0.90 | NT5E (0.56) | NT5E | |
| SCHEMBL23006827 | 0.85 | NT5E (0.54) | NT5E | |
| SCHEMBL22614528 | 0.84 | NT5E (0.57) | NT5E | |
| SCHEMBL26720428 | 0.83 | NT5E (0.54) | NT5E | |
| SCHEMBL22975424 | 0.83 | NT5E (0.59) | NT5E | |
| SCHEMBL20524245 | 0.83 | NT5E (0.76) | NT5E | |
| SCHEMBL20180065 | 0.83 | NT5E (0.51) | NT5E | |
| SCHEMBL21840057 | 0.81 | NT5E (0.56) | NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259253-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-20220259253-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2022-08-18 | — | — | US | disclosed |
| US-11377469-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377469-B2 | CD73 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ARCUS BIOSCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200347090-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200347090-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200062797-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ARCUS BIOSCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2018094148-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ARCUS BIOSCIENCES, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347090-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-11377469-B2 | CD73 inhibitors | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20220259253-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-20200062797-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ENTPD5, NT5E, ENTPD1 | NT5E 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.